216 related articles for article (PubMed ID: 31942615)
1. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection.
Tangye SG; Latour S
Blood; 2020 Feb; 135(9):644-655. PubMed ID: 31942615
[TBL] [Abstract][Full Text] [Related]
2. Genetic susceptibility to EBV infection: insights from inborn errors of immunity.
Tangye SG
Hum Genet; 2020 Jun; 139(6-7):885-901. PubMed ID: 32152698
[TBL] [Abstract][Full Text] [Related]
3. Editorial: EBV Infection and Human Primary Immune Deficiencies.
Cohen JI; Meyts I
Front Immunol; 2020; 11():130. PubMed ID: 32117278
[No Abstract] [Full Text] [Related]
4. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
5. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
7. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
8. Immunological aspects of Epstein-Barr virus infection.
Ohga S; Nomura A; Takada H; Hara T
Crit Rev Oncol Hematol; 2002 Dec; 44(3):203-15. PubMed ID: 12467961
[TBL] [Abstract][Full Text] [Related]
9. Human immunity against EBV-lessons from the clinic.
Tangye SG; Palendira U; Edwards ES
J Exp Med; 2017 Feb; 214(2):269-283. PubMed ID: 28108590
[TBL] [Abstract][Full Text] [Related]
10. The evolving therapeutic approaches for Epstein-Barr virus infection in immunocompetent and immunocompromised individuals.
Okano M
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Jun; 3(2):137-42. PubMed ID: 12769785
[TBL] [Abstract][Full Text] [Related]
11. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV
Hernández DM; Valderrama S; Gualtero S; Hernández C; López M; Herrera MV; Solano J; Fiorentino S; Quijano S
Front Immunol; 2018; 9():2291. PubMed ID: 30337929
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Epstein-Barr virus (EBV) BZLF1 gene promoter variants and comparison of cellular gene expression profiles in Japanese patients with infectious mononucleosis, chronic active EBV infection, and EBV-associated hemophagocytic lymphohistiocytosis.
Imajoh M; Hashida Y; Murakami M; Maeda A; Sato T; Fujieda M; Wakiguchi H; Daibata M
J Med Virol; 2012 Jun; 84(6):940-6. PubMed ID: 22511310
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases.
Yachie A; Kanegane H; Kasahara Y
Semin Hematol; 2003 Apr; 40(2):124-32. PubMed ID: 12704589
[TBL] [Abstract][Full Text] [Related]
15. Mucocutaneous manifestations of Epstein-Barr virus infection.
Mendoza N; Diamantis M; Arora A; Bartlett B; Gewirtzman A; Tremaine AM; Tyring S
Am J Clin Dermatol; 2008; 9(5):295-305. PubMed ID: 18717604
[TBL] [Abstract][Full Text] [Related]
16. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
17. Virological aspects of Epstein-Barr virus infections.
Yamashita N; Kimura H; Morishima T
Acta Med Okayama; 2005 Dec; 59(6):239-46. PubMed ID: 16418766
[TBL] [Abstract][Full Text] [Related]
18. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
19. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.
Li FY; Chaigne-Delalande B; Su H; Uzel G; Matthews H; Lenardo MJ
Blood; 2014 Apr; 123(14):2148-52. PubMed ID: 24550228
[TBL] [Abstract][Full Text] [Related]
20. [Regulation and evasion of host immune responses by Epstein-Barr virus].
Xiao N; Chen Q; Cai S
Wei Sheng Wu Xue Bao; 2016 Jan; 56(1):19-25. PubMed ID: 27305776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
